<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39435093</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Establishment of national standards of SARS-CoV-2 variants in Taiwan.</ArticleTitle><Pagination><StartPage>e38275</StartPage><MedlinePgn>e38275</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e38275</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e38275</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">In response to the pandemic, the Taiwan Food and Drug Administration (TFDA) established an initial SARS-CoV-2 RNA national standard based on the original Wuhan strain. However, with the depletion of the first national standard and continued mutation of the virus, the establishment of new national standards was imminent.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Hence, new candidate national standards were established by heat-inactivation for 30 min for six representative strains of SARS-CoV-2, comprising the original strain and five variants with anticipated concentrations of 7.70 Log<sub>10</sub> international units (IU)/mL each. To enhance the credibility of these national standards, the TFDA extended invitations to both domestic and international institutions to participate in a collaborative study. A total of eight participants contributed eleven datasets, incorporating two methods and targeting four distinct genes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Based on these collective findings, the quantified viral RNA concentrations for each SARS-CoV-2 national standard strain are 7.69, 7.70, 7.69, 7.44, 7.52, and 7.29 Log<sub>10</sub> IU/mL with Wuhan, alpha, beta, gamma, delta, and omicron strain, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">These newly established national standards will continue to be made available to the industry, serving as a fundamental reference for the development and quality control of nucleic acid <i>in vitro</i> diagnostic (IVD) reagents in Taiwan.</AbstractText><CopyrightInformation>© 2024 Taiwan Food and Drug Administration.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Ming-Sian</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Research and Analysis, Food and Drug Administration, Ministry of Health and Welfare, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Pu-Chieh</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Division of Research and Analysis, Food and Drug Administration, Ministry of Health and Welfare, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Po-Lin</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Division of Research and Analysis, Food and Drug Administration, Ministry of Health and Welfare, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tso</LastName><ForeName>Chun-Hsi</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Division of Research and Analysis, Food and Drug Administration, Ministry of Health and Welfare, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hsin-Mei</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Division of Research and Analysis, Food and Drug Administration, Ministry of Health and Welfare, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yi-Hsuan</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Division of Research and Analysis, Food and Drug Administration, Ministry of Health and Welfare, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Po-Chih</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Division of Research and Analysis, Food and Drug Administration, Ministry of Health and Welfare, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Jia-Chuan</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Research and Analysis, Food and Drug Administration, Ministry of Health and Welfare, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Der-Yuan</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Division of Research and Analysis, Food and Drug Administration, Ministry of Health and Welfare, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Collaborate study</Keyword><Keyword MajorTopicYN="N">RT-dPCR</Keyword><Keyword MajorTopicYN="N">RT-qPCR</Keyword><Keyword MajorTopicYN="N">VOC</Keyword><Keyword MajorTopicYN="N">Variant strains</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>4</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39435093</ArticleId><ArticleId IdType="pmc">PMC11491896</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e38275</ArticleId><ArticleId IdType="pii">S2405-8440(24)14306-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu D., et al. The SARS-CoV-2 outbreak: what we know. Int. J. Infect. Dis. 2020;94:44–48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102543</ArticleId><ArticleId IdType="pubmed">32171952</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization W.H. WHO coronavirus (COVID-19) dashboard. 2023. https://covid19.who.int/ Available from:</Citation></Reference><Reference><Citation>La Marca A., et al. Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. Reprod. Biomed. Online. 2020;41(3):483–499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7293848</ArticleId><ArticleId IdType="pubmed">32651106</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhen W., et al. Comparison of four molecular in vitro diagnostic assays for the detection of SARS-CoV-2 in nasopharyngeal specimens. J. Clin. Microbiol. 2020;58(8) doi: 10.1128/jcm.00743-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.00743-20</ArticleId><ArticleId IdType="pmc">PMC7383517</ArticleId><ArticleId IdType="pubmed">32341143</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorta-Gorrín A., et al. Detection of SARS-CoV-2 based on nucleic acid amplification tests (NAATs) and its integration into nanomedicine and microfluidic devices as point-of-care testing (POCT) Int. J. Mol. Sci. 2023;24(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10299269</ArticleId><ArticleId IdType="pubmed">37373381</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin P.-L., et al. A collaborative study to establish the national standard for SARS-CoV-2 RNA nucleic acid amplification techniques (NAAT) in Taiwan. Biologicals. 2022;79:31–37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9428600</ArticleId><ArticleId IdType="pubmed">36085128</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo H.M., Kim I.-H., Kim S. Nucleic acid testing of SARS-CoV-2. Int. J. Mol. Sci. 2021;22(11):6150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8201071</ArticleId><ArticleId IdType="pubmed">34200331</ArticleId></ArticleIdList></Reference><Reference><Citation>Mistry P., et al. SARS-CoV-2 variants, vaccines, and host immunity. Front. Immunol. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8761766</ArticleId><ArticleId IdType="pubmed">35046961</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavda V.P., Patel A.B., Vaghasiya D.D. SARS‐CoV‐2 variants and vulnerability at the global level. J. Med. Virol. 2022;94(7):2986–3005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9088647</ArticleId><ArticleId IdType="pubmed">35277864</ArticleId></ArticleIdList></Reference><Reference><Citation>Caza M., et al. Evaluation of the clinical and analytical performance of the Seegene allplex™ SARS-CoV-2 variants I assay for the detection of variants of concern (VOC) and variants of interests (VOI) J. Clin. Virol. 2021;144</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8487322</ArticleId><ArticleId IdType="pubmed">34628158</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung C., et al. Omicron: what makes the latest SARS-CoV-2 variant of concern so concerning? J. Virol. 2022;96(6) 21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8941872</ArticleId><ArticleId IdType="pubmed">35225672</ArticleId></ArticleIdList></Reference><Reference><Citation>He X., et al. SARS‐CoV‐2 Omicron variant: characteristics and prevention. MedComm. 2021;2(4):838–845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8693031</ArticleId><ArticleId IdType="pubmed">34957469</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.-I., et al. Development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) thermal inactivation method with preservation of diagnostic sensitivity. J. Microbiol. 2020;58:886–891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7522010</ArticleId><ArticleId IdType="pubmed">32989642</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C., et al. Policy decisions and use of information technology to fight coronavirus disease, Taiwan. Emerg. Infect. Dis. 2020;26(7):1506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323533</ArticleId><ArticleId IdType="pubmed">32228808</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksamentov I., Roemer C., Hodcroft E.B., Neher R.A. Nextclade: clade assignment, mutation calling and quality control for viral genomes. J. Open Source Softw. 2021;6(67):3773.</Citation></Reference><Reference><Citation>Davies N.G., et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England. Science. 2021;372(6538)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8128288</ArticleId><ArticleId IdType="pubmed">33658326</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong T., et al. Diagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives. Chem. Sci. 2023;14(23):6149–6206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10266450</ArticleId><ArticleId IdType="pubmed">37325147</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider K., et al. Psoralen inactivation of viruses: a process for the safe manipulation of viral antigen and nucleic acid. Viruses. 2015;7(11):5875–5888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664985</ArticleId><ArticleId IdType="pubmed">26569291</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence R.M., Zook J.D., Hogue B.G. Full inactivation of alphaviruses in single particle and crystallized forms. J. Virol Methods. 2016;236:237–244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6457655</ArticleId><ArticleId IdType="pubmed">27465218</ArticleId></ArticleIdList></Reference><Reference><Citation>Madani T.A., et al. Thermal inactivation of Alkhumra hemorrhagic fever virus. Arch. Virol. 2014;159:2687–2691.</Citation><ArticleIdList><ArticleId IdType="pubmed">24906524</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton J., et al. The effect of a non-denaturing detergent and a guanidinium-based inactivation agent on the viability of Ebola virus in mock clinical serum samples. J. Virol Methods. 2017;250:34–40.</Citation><ArticleIdList><ArticleId IdType="pubmed">28941617</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilms C., et al. Exact determination of UV-induced crosslinks in 16S ribosomal RNA in 30S ribosomal subunits. Rna. 1997;3(6):602–612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1369509</ArticleId><ArticleId IdType="pubmed">9174095</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell S.W., McCORMICK J.B. Physicochemical inactivation of Lassa, Ebola, and Marburg viruses and effect on clinical laboratory analyses. J. Clin. Microbiol. 1984;20(3):486–489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC271356</ArticleId><ArticleId IdType="pubmed">6490832</ArticleId></ArticleIdList></Reference><Reference><Citation>Darnell M.E., et al. Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV. J. Virol Methods. 2004;121(1):85–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112912</ArticleId><ArticleId IdType="pubmed">15350737</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>